News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2017

Epigenomics AG reduziert Prognose für das Geschäftsjahr 2017

PDF 6. Juli 2017 – Die Epigenomics AG (FSE: ECX; OTCQX: EPGNY) hat heute den Ausblick für das Geschäftsjahr 2017 gesenkt. Aufgrund unterhalb der Erwartungen liegender Umsätze im ersten Halbjahr 2017 (etwa EUR 0,5 Mio.) sowie dem erwarteten Ausbleiben der Kostenerstattung im US-Markt im weiteren Jahresverlauf geht die Gesellschaft nunmehr von einem Umsatz von EUR 1,0 […]

Read more

Epigenomics AG issues change in guidance for financial year 2017

PDF July 6, 2017 – Epigenomics AG (FSE: ECX; OTCQX: EPGNY) today lowered its financial outlook for the financial year 2017. Based on lower than expected revenues in the first half of 2017 (H1 2017: approximately EUR 0.5 million), and the continued lack of reimbursement coverage anticipated for the remainder of the year in the U.S. […]

Read more

Epigenomics AG: Executive Board and Supervisory Board recommend acceptance of the voluntary public takeover offer

PDF Berlin, 14 June 2017 – The Executive Board and Supervisory Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY) have evaluated the voluntary public takeover offer of Summit Hero Holding GmbH (“Bidder”) and have published their statement pursuant to section 27 of the German Takeover Act (Wertpapiererwerbs- und Übernahmeangebot ‑ WpÜG). The Executive Board […]

Read more

Offer document published for the voluntary public takeover offer for Epigenomics AG

PDF Berlin, 8 June 2017 – Today Summit Hero Holding GmbH published the offer document for the voluntary takeover offer for all outstanding shares of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY). This marks the beginning of the acceptance period, in which Epigenomics shareholders can accept the cash offer of 7.52 Euros per share. […]

Read more

Epigenomics’ Annual General Meeting: CEO touts takeover offer

· Takeover offer is in the best interests of Epigenomics and its shareholders · Shareholders approved all agenda items according to the Board’s proposal   Berlin, 31 May 2017 – The speech from Greg Hamilton, CEO of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), at yesterday’s Annual General Meeting in Berlin focused primarily on […]

Read more

Epigenomics AG announces 2017 First Quarter Financial Results

Berlin (Germany) and Germantown, MD (U.S.A.), May 10, 2017 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY), or the “Company”, today announced its financial results for the first quarter 2017 ended March 31. Q1/2017 Financial results Total revenue slightly decreased to EUR 281 thousand (Q1 2016: EUR 295 thousand) mainly due to the termination of a […]

Read more